These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 20465434)

  • 21. Consumption of an n-3 polyunsaturated fatty acid-enriched dip modulates plasma lipid profile in subjects with diabetes type II.
    Garg ML; Blake RJ; Clayton E; Munro IA; Macdonald-Wicks L; Singh H; Moughan PJ
    Eur J Clin Nutr; 2007 Nov; 61(11):1312-7. PubMed ID: 17299483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The effect of fatty compounds with different ratios of the polyunsaturated fatty acids of the omega-3 and omega-6 families on the expression of food-related anaphylaxis, on the liver cytochrome P-450 system and on 17-hydroxycorticosteroid metabolism in guinea pigs].
    Malikova NA; Krzhechkovskaia VV; Marokko IN; Mazo VK
    Vopr Pitan; 1995; (4):13-6. PubMed ID: 7483473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Restriction of dietary calories, fat and iron improves non-alcoholic fatty liver disease.
    Yamamoto M; Iwasa M; Iwata K; Kaito M; Sugimoto R; Urawa N; Mifuji R; Konishi M; Kobayashi Y; Adachi Y
    J Gastroenterol Hepatol; 2007 Apr; 22(4):498-503. PubMed ID: 17376040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of n-3 fatty acids on C-reactive protein levels in patients with chronic renal failure.
    Madsen T; Schmidt EB; Christensen JH
    J Ren Nutr; 2007 Jul; 17(4):258-63. PubMed ID: 17586424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of foods enriched with n-3 long-chain polyunsaturated fatty acids on erythrocyte n-3 levels and cardiovascular risk factors.
    Murphy KJ; Meyer BJ; Mori TA; Burke V; Mansour J; Patch CS; Tapsell LC; Noakes M; Clifton PA; Barden A; Puddey IB; Beilin LJ; Howe PR
    Br J Nutr; 2007 Apr; 97(4):749-57. PubMed ID: 17349088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adiponectin is involved in the protective effect of DHEA against metabolic risk in aged rats.
    Pérez-de-Heredia F; Sánchez J; Priego T; Nicolás F; Portillo Mdel P; Palou A; Zamora S; Garaulet M
    Steroids; 2008 Oct; 73(11):1128-36. PubMed ID: 18534650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Consumption of n-3 polyunsaturated fatty acid-enriched eggs and changes in plasma lipids of human subjects.
    Jiang Z; Sim JS
    Nutrition; 1993; 9(6):513-8. PubMed ID: 7906572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Omega-3 fatty acids as an option in the treatment of NAFLD].
    Singer P
    MMW Fortschr Med; 2011 Oct; 153 Suppl 3():90-4. PubMed ID: 22184802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease.
    Di Minno MN; Russolillo A; Lupoli R; Ambrosino P; Di Minno A; Tarantino G
    World J Gastroenterol; 2012 Nov; 18(41):5839-47. PubMed ID: 23139599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low concentrations of serum n-3 polyunsaturated fatty acids in non-alcoholic fatty liver disease patients with liver injury.
    Kishino T; Ohnishi H; Ohtsuka K; Matsushima S; Urata T; Watanebe K; Honda Y; Mine Y; Matsumoto M; Nishikawa K; Mori H; Takahashi S; Ishida H; Watanabe T
    Clin Chem Lab Med; 2011 Jan; 49(1):159-62. PubMed ID: 21034259
    [No Abstract]   [Full Text] [Related]  

  • 31. Role of nitric oxide in the treatment of non-alcoholic fatty liver by omega-3 fatty acids.
    Beyazit Y; Purnak T; Kekilli M
    Aliment Pharmacol Ther; 2010 Jul; 32(2):303-4. PubMed ID: 20636624
    [No Abstract]   [Full Text] [Related]  

  • 32. Is there any consensus as to what diet or lifestyle approach is the right one for NAFLD patients?
    Finelli C; Tarantino G
    J Gastrointestin Liver Dis; 2012 Sep; 21(3):293-302. PubMed ID: 23012671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The optimal dose of omega-3 supplementation for non-alcoholic fatty liver disease.
    Li Y; Chen D
    J Hepatol; 2012 Aug; 57(2):468-9; author reply 469-70. PubMed ID: 22433603
    [No Abstract]   [Full Text] [Related]  

  • 34. Incorporation of n-3 polyunsaturated fatty acids into processed foods.
    Gibney MJ
    Br J Nutr; 1997 Aug; 78(2):193-5. PubMed ID: 9301409
    [No Abstract]   [Full Text] [Related]  

  • 35. [Waist-to-hip ratio is a superior predictor for non-alcoholic simple fatty liver].
    Jiang L; Chen XW; Zheng RD; Chen J; Meng JR; Xu MY; Qu Y; Lu LG
    Zhonghua Gan Zang Bing Za Zhi; 2010 Nov; 18(11):859-61. PubMed ID: 21138638
    [No Abstract]   [Full Text] [Related]  

  • 36. Omega-3 fatty acids: a promising alternative treatment approach for patients with nonalcoholic fatty liver disease.
    Beyazit Y; Purnak T; Kekilli M
    Dig Dis Sci; 2010 Aug; 55(8):2422-3; author reply 2423. PubMed ID: 20521114
    [No Abstract]   [Full Text] [Related]  

  • 37. The use of omega-3 Fatty acids in nonalcoholic Fatty liver disease: the end of the road or a new beginning?
    Alkhouri N
    J Pediatr; 2015 Jun; 166(6):1335-7. PubMed ID: 25851650
    [No Abstract]   [Full Text] [Related]  

  • 38. Coumarin: an alternative candidate for the treatment of non-alcoholic steatohepatitis?
    Wu J
    Br J Nutr; 2013 May; 109(9):1542-3. PubMed ID: 23340308
    [No Abstract]   [Full Text] [Related]  

  • 39. [2nd prize in the competition of young scientists in the XVIII National Congress "Man and Medicine" of 2011].
    Andreev DN
    Eksp Klin Gastroenterol; 2011; (8):102-4. PubMed ID: 22629765
    [No Abstract]   [Full Text] [Related]  

  • 40. Reply: To PMID 24818764.
    Sanyal AJ;
    Gastroenterology; 2015 Jan; 148(1):262-3. PubMed ID: 25451655
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.